Solvonis Therapeutics plc

Graft Polymer, now transitioning to Solvonis Therapeutics plc, is an innovative biotechnology company focused on developing intellectual property related to the treatment of mental health and substance use disorders, and co-developing therapeutics for these conditions. Our mission is to improve outcomes for individuals suffering from these disorders, with an initial focus on trauma-related mental health conditions, such as PTSD. PTSD affected approximately 13 million adults in the U.S. in 2020, with the Company estimating a current affected population of 20 million across the U.S., UK, and key EU markets.